Glycemic Control and Aspirin Resistance in Patients Taking Low-Dose Aspirin for Pre-eclampsia Prevention
| Autor: | Steven G. Gabbe, Kara M. Rood, Mark B. Landon, Douglas A. Kniss, Marwan Ma'ayeh, Stephen E. Gee |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Glycated Hemoglobin
medicine.medical_specialty Aspirin Eclampsia Randomization business.industry Obstetrics and Gynecology Glycemic Control medicine.disease Placebo Gastroenterology Pre-Eclampsia Pregnancy Interquartile range Internal medicine Pediatrics Perinatology and Child Health medicine Humans Gestation Female Hemoglobin business Glycemic medicine.drug |
| Zdroj: | American Journal of Perinatology. 39:349-353 |
| ISSN: | 1098-8785 0735-1631 |
| Popis: | OBJECTIVES To assess the association between aspirin and glycemic control in diabetic, pregnant patients, and the risk for aspirin resistance in those with poor glycemic control across gestation taking low-dose aspirin (LDA) for pre-eclampsia (PEC) prevention. STUDY DESIGN We performed a secondary analysis of samples collected during the Maternal-Fetal Medicine Units trial of LDA for PEC prevention. A subset of insulin-controlled diabetic patient samples on placebo or 60 mg aspirin daily were evaluated. Glycosylated hemoglobin was measured at randomization, mid-second trimester, and third trimester time points. Thromboxane B2 (TXB2) measurements were previously assessed as part of the original study. Primary outcome was the effect of LDA on glycosylated hemoglobin levels compared with placebo across gestation. RESULTS Levels of glycosylated hemoglobin increased across gestation in the placebo group (2,067.7 [interquartile range, IQR: 1,624.6-2,713.5 µg/mL] vs. 2,461.9 [1,767.0-3,209.9 µg/mL] vs. 3,244.3 [2,691.5-4,187.0 µg/mL]; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|